grant
Targeted degradation of CDK4 and 6 to overcome treatment resistance in breast cancer
Organization UT SOUTHWESTERN MEDICAL CENTERLocation DALLAS, UNITED STATESPosted 23 Jun 2025Deadline 31 May 2030
NIHUS FederalResearch GrantFY20253-D3-Dimensional3DAnti-EstrogensBreast CancerBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineBreast Tumor PatientBreast tumor cell lineCDK4CDK4 geneCaringCell BodyCell CycleCell Division CycleCell Division Kinase 4Cell LineCellLineCellsChromatinClinicalCyclin-Dependent Kinase 4DataDependenceDevelopmentER PositiveER+Endocrine TherapyEngineeringEngraftmentEstrogen AntagonistsEstrogen receptor positiveEstrogensFDA approvedFaslodexFulvestrantGeneralized GrowthGenomicsGrowthHeterograftHeterologous TransplantationHormonal TherapyICI 182,780ICI 182780In VitroInvestigationKinasesMachine LearningMalignant Breast NeoplasmOutcomeP105-RBPDX modelPP110PSK-J3Patient derived xenograftPatientsPhosphorylationPhosphotransferase GenePhosphotransferasesPrimary NeoplasmPrimary TumorProtacProtein PhosphorylationProteolysis targeting chimericRb Gene ProductRb ProteinRb1 Gene ProductResistanceResistance developmentResistant developmentRetinoblastoma Associated ProteinRetinoblastoma ProteinRoleSYS-TXSamplingStrains Cell LinesSystemic TherapyTechniquesTestingTherapeutic EstrogenTissue GrowthTransphosphorylasesTreatment EfficacyXenograftXenograft ModelXenograft procedureXenotransplantationantiestrogenantiestrogenicbreast tumor cellcheck point inhibitioncheckpoint inhibitioncultured cell linedetermine efficacydeveloping resistancedevelopmentaleffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationestrogen inhibitorevaluate efficacyexamine efficacyhormone therapyhumanized micehumanized mouseimmune check point inhibitionimmune checkpoint inhibitionimprovedin vivoindividuals with breast cancerinhibitorintervention efficacymachine based learningmalignant breast tumormouse modelmurine modelmutantnew approachesnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel approachesnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachontogenyoverexpressoverexpressionpRBpatient derived xenograft modelpatients with breast cancerperson with breast cancerpharmacologicprotein expressionproteolysis targeting chimaeraproteolysis targeting chimeraresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapysocial roletherapeutic efficacytherapeutic resistancetherapy efficacytherapy resistantthree dimensionaltranscriptional reprogrammingtreatment resistancetumortumor growthxeno-transplantxeno-transplantationxenograft transplant modelxenotransplant model
Description preview
Abstract
Although CDK4/6 inhibitors (in combination with an endocrine therapy) are the preferred systemic therapy for
treatment of patients with metastatic, Estrogen Receptor-positive (ER+) breast cancer (BC), development of
resistance to CDK4/6 inhibitors is universal. Therefore, development of novel therapeutic strategies to target
CDK4/6…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click